Related Experiment Video
Updated: Jul 15, 2026
07:22
Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
[Leptin: a link between obesity and osteoarthritis?]
Bernard Terlain1, Nathalie Presle, Pascale Pottie
1Physiopathologie et pharmacologie articulaires, Faculté de médecine, avenue de la forêt de Haye, BP 184, 54505, Vandceuvre les Nancy.
Bulletin De L'Academie Nationale De Medecine
|April 25, 2007
Summary
Obesity, a common cause of osteoarthritis (OA), is linked to altered lipid metabolism and adipokine levels in joints. Research suggests leptin plays a key role in OA development and cartilage destruction.
Area of Science:
- Biochemistry
- Metabolic disease
- Rheumatology
Context:
- Osteoarthritis (OA) is a prevalent degenerative joint disease.
- Obesity is a major risk factor for OA, alongside aging.
- Altered lipid metabolism and systemic factors contribute to OA pathogenesis.
Purpose:
- To investigate the role of adipokines, particularly leptin, in osteoarthritis.
- To explore the hypothesis that OA is a systemic metabolic disease linked to lipid disorders.
- To examine the relationship between adipokine levels and joint homeostasis in OA.
Summary:
- Obesity contributes to osteoarthritis (OA) through mechanical loading and systemic factors, including altered lipid metabolism.
- OA may be a metabolic disease where lipid disorders affect joint homeostasis, influenced by local adipokine levels.
- Joints in OA patients show increased leptin and decreased adiponectin and resistin levels compared to plasma.
- Evidence includes leptin overexpression in OA cartilage, correlation with cartilage destruction, leptin synthesis by osteophytes, and elevated leptin in female OA patients' joints.
Impact:
- The link between OA and adipokines offers new avenues for OA prevention strategies.
- Identifies adipokines, especially leptin, as potential therapeutic targets for osteoarthritis.
- Highlights the systemic metabolic nature of OA and its connection to lipid disorders.
Related Concept Videos
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:19Psychoneuroimmunology: Diabetes and Cancer
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...